Literature DB >> 27444038

Loxoprofen: A Review in Pain and Inflammation.

Sarah L Greig1, Karly P Garnock-Jones2.   

Abstract

Loxoprofen (Loxonin(®), Loxonin(®) Pap, Loxonin(®) Tape) is a prodrug-type NSAID that is available in several formulations, including 60 mg tablets, 100 mg hydrogel patches and 50 or 100 mg tape. In active comparator-controlled trials, oral loxoprofen therapy (ranging from 2 days to 6 weeks' duration depending on the pain type) provided analgesic efficacy that generally did not significantly differ from that of celecoxib for postoperative pain or frozen shoulder, ibuprofen for knee osteoarthritis or naproxen for lumbar pain. In double-blind, double-dummy, multicentre trials, loxoprofen hydrogel patches were noninferior to oral loxoprofen with regard to rates of final overall symptomatic improvement over 1-4 weeks in patients with knee osteoarthritis, myalgia or trauma-induced swelling and pain. Loxoprofen hydrogel patches were also noninferior to other commercially available patches (ketoprofen and indometacin) over 2 or 4 weeks in patients with knee osteoarthritis or myalgia in open-label studies. Oral and topical loxoprofen were generally well tolerated in clinical trials. Thus, loxoprofen is a useful analgesic option for patients with pain and inflammation, with topical loxoprofen potentially reducing the risk of gastrointestinal, cardiovascular and renal complications associated with oral NSAID use.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27444038     DOI: 10.1007/s40261-016-0440-9

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  23 in total

1.  Diagnosis and treatment of osteoarthritis.

Authors: 
Journal:  Orthop Surg       Date:  2010-02       Impact factor: 2.071

2.  Dermatopharmacokinetic bioequivalence study of two types of topical patches containing loxoprofen sodium.

Authors:  Xia Chen; Qian Zhao; Ei Hitsu; Ji Jiang; Wen Zhong; Takayasu Matsuzawa; Pei Hu
Journal:  Int J Clin Pharmacol Ther       Date:  2014-10       Impact factor: 1.366

3.  Loxoprofen sodium and celecoxib for postoperative pain in patients after spinal surgery: a randomized comparative study.

Authors:  Hiroyuki Sekiguchi; Gen Inoue; Toshiyuki Nakazawa; Takayuki Imura; Wataru Saito; Kentaro Uchida; Masayuki Miyagi; Naonobu Takahira; Masashi Takaso
Journal:  J Orthop Sci       Date:  2015-04-25       Impact factor: 1.601

4.  Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.

Authors:  C Sakamoto; T Kawai; S Nakamura; T Sugioka; J Tabira
Journal:  Aliment Pharmacol Ther       Date:  2012-12-10       Impact factor: 8.171

5.  Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys.

Authors:  François Rannou; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Semin Arthritis Rheum       Date:  2015-12-02       Impact factor: 5.532

6.  Evaluation of selective cyclooxygenase-2 inhibitor-induced small bowel injury: randomized cross-over study compared with loxoprofen in healthy subjects.

Authors:  Kazuhiro Mizukami; Kazunari Murakami; Mika Yamauchi; Osamu Matsunari; Ryo Ogawa; Yoshifumi Nakagawa; Tadayoshi Okimoto; Masaaki Kodama; Toshio Fujioka
Journal:  Dig Endosc       Date:  2012-09-25       Impact factor: 7.559

Review 7.  NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians.

Authors:  James M Scheiman
Journal:  J Clin Gastroenterol       Date:  2016-01       Impact factor: 3.062

8.  Effects of loxoprofen sodium, a newly synthesized non-steroidal anti-inflammatory drug, and indomethacin on gastric mucosal haemodynamics in the human.

Authors:  S Kawano; S Tsuji; N Hayashi; Y Takei; K Nagano; H Fusamoto; T Kamada
Journal:  J Gastroenterol Hepatol       Date:  1995 Jan-Feb       Impact factor: 4.029

Review 9.  Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs.

Authors:  Nicholas Moore; Charles Pollack; Paul Butkerait
Journal:  Ther Clin Risk Manag       Date:  2015-07-15       Impact factor: 2.423

10.  Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.

Authors:  Carmelo Scarpignato; Angel Lanas; Corrado Blandizzi; Willem F Lems; Matthias Hermann; Richard H Hunt
Journal:  BMC Med       Date:  2015-03-19       Impact factor: 8.775

View more
  10 in total

1.  Mechanism-Driven Read-Across of Chemical Hepatotoxicants Based on Chemical Structures and Biological Data.

Authors:  Linlin Zhao; Daniel P Russo; Wenyi Wang; Lauren M Aleksunes; Hao Zhu
Journal:  Toxicol Sci       Date:  2020-04-01       Impact factor: 4.849

2.  The Anti-Inflammation and Anti-Nociception Effect of Ketoprofen in Rats Could Be Strengthened Through Co-Delivery of a H2S Donor, S-Propargyl-Cysteine.

Authors:  Yue Yu; Qinyan Yang; Zhou Wang; Qian Ding; Meng Li; Yudong Fang; Qida He; Yi Zhun Zhu
Journal:  J Inflamm Res       Date:  2021-11-09

3.  Development of omega-3 loxoprofen-loaded nanoemulsion to limit the side effect associated with NSAIDs in treatment of tooth pain.

Authors:  Khaled M Hosny; Amal M Sindi; Hala M Alkhalidi; Mallesh Kurakula; Amira H Hassan; Rana B Bakhaidar; Walaa A Abualsunun; Alshaimaa M Almehmady; Ahmed Khames; Waleed Y Rizg; Rasha A Khallaf; Nabil K Alruwaili; Nabil A Alhakamy
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

4.  Anti-Inflammatory, Analgesic and Antioxidant Potential of New (2S,3S)-2-(4-isopropylbenzyl)-2-methyl-4-nitro-3-phenylbutanals and Their Corresponding Carboxylic Acids through In Vitro, In Silico and In Vivo Studies.

Authors:  Fawad Mahmood; Jamshaid Ali Khan; Mater H Mahnashi; Muhammad Saeed Jan; Muhammad Aamir Javed; Umer Rashid; Abdul Sadiq; Syed Shams Ul Hassan; Simona Bungau
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

5.  Solubility Optimization of Loxoprofen as a Nonsteroidal Anti-Inflammatory Drug: Statistical Modeling and Optimization.

Authors:  Mohammed Alqarni; Nader Ibrahim Namazi; Sameer Alshehri; Ibrahim A Naguib; Amal M Alsubaiyel; Kumar Venkatesan; Eman Mohamed Elmokadem; Mahboubeh Pishnamazi; Mohammed A S Abourehab
Journal:  Molecules       Date:  2022-07-07       Impact factor: 4.927

6.  Exploring the Metabolism of Loxoprofen in Liver Microsomes: The Role of Cytochrome P450 and UDP-Glucuronosyltransferase in Its Biotransformation.

Authors:  Riya Shrestha; Pil Joung Cho; Sanjita Paudel; Aarajana Shrestha; Mi Jeong Kang; Tae Cheon Jeong; Eung-Seok Lee; Sangkyu Lee
Journal:  Pharmaceutics       Date:  2018-08-02       Impact factor: 6.321

7.  Irreversible profound symptomatic bradycardia requiring pacemaker after tizanidine/loxoprofen combination therapy: a case report.

Authors:  Xiaolin Li; Yunpeng Jin
Journal:  J Int Med Res       Date:  2018-03-27       Impact factor: 1.671

8.  Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators.

Authors:  Sanjita Paudel; Aarajana Shrestha; Piljoung Cho; Riya Shrestha; Younah Kim; Taeho Lee; Ju-Hyun Kim; Tae Cheon Jeong; Eung-Seok Lee; Sangkyu Lee
Journal:  Pharmaceutics       Date:  2019-09-16       Impact factor: 6.321

9.  Evaluation of the Percutaneous Absorption of Drug Molecules in Zebrafish.

Authors:  Daizo Morikane; Liqing Zang; Norihiro Nishimura
Journal:  Molecules       Date:  2020-08-31       Impact factor: 4.411

10.  Effect of Combined Bee Venom Acupuncture and NSAID Treatment for Non-Specific Chronic Neck Pain: A Randomized, Assessor-Blinded, Pilot Clinical Trial.

Authors:  Boram Lee; Byung-Kwan Seo; O-Jin Kwon; Dae-Jean Jo; Jun-Hwan Lee; Sanghun Lee
Journal:  Toxins (Basel)       Date:  2021-06-23       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.